Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Environmental, Social & Governance
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Bone Marrow Conditioning
    • Clinical Trials
    • Illuccix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
    • Investor Centre
    • Financial Reports & Presentations
    • Corporate Governance
    • ASX Announcements
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home Investor Centre

Investor Centre

Welcome to the Telix Investor Centre. Here you will find our ASX announcements, annual reports, presentations and important information to help you manage your shareholding.

ASX: TLX Share Price

Last updated:

Price
Movement +/-
Volume
Daily High
Daily Low
52 Week Range /
Market Cap.

Share Price History

Share price from to Download Data

Range

Compare against

Show

ASX Announcements

ASX Announcements

ASX Announcements  

Financial Reports & Presentations

Financial Reports & Presentations

Financial Reports & Presentations  

Corporate Governance

Corporate Governance

Corporate Governance  

Spotlight

FDA Approves Expanded Indication for Telix’s Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

Telix Pharmaceuticals today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application…

Read More   

Quick Links

Annual Report  

Latest Investor Presentation  

Half Year Financial Report  

Latest Investor Conference Call  

4C Quarterly Cash Flow Report  

Subscribe

* indicates required
Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings

Recent legislative changes to the Corporations Act 2001 (Cth), which came into effect on 1 April 2022, mean there are new options available to shareholders as to how you elect to receive your communications from Telix. Telix will no longer send shareholders physical meeting documents unless you request a copy to be mailed.

Telix encourages shareholders to provide your email address so we can communicate with you electronically when shareholder notices become available online for such items as meeting documents, dividend statements (if applicable) and annual reports. You can make a standing election to receive some or all of your shareholder communications in physical or electronic form.

To review or update your current communication preference simply logon to our share registry’s website here. You will need your portfolio log in details or your Shareholder Reference Number (SRN) or Holder Identification Number (HIN). Once logged in, select the ‘communications’ tab at the top of the page.

If at any time you require an additional copy of a communication, or you need more information about the options available to you, you may contact Link Market Services via email at LMSComms@linkmarketservices.com.au